On the desk today · Royalty Pharma
No labs. No pills. Just a royalty on every prescription.
| NASDAQ · RPRX |
Where should you invest $100 right now?
Elon Musk just invented and patented this new AI technology…
And he's predicting it will launch a NEW industry that will grow more than 7 million percent in the coming years.
Even if he's only 10% right, that would still be enough to grow $100 into more than $700,000.
The Pharmacist Who Never
Filled a Prescription
In the early 1990s, a young Mexican-born investment banker at Lazard Frères in New York noticed something strange. A group of wealthy clients at PaineWebber had quietly invested in the royalty stream of a chemotherapy drug — and they were getting paid every time a doctor wrote a prescription. The banker's name was Pablo Legorreta. He didn't know much about chemistry. But he understood a toll booth when he saw one.
I thought about this the other day while picking up a prescription at the pharmacy. I watched the pharmacist scan the barcode. The insurance company paid. The drug company collected its revenue. And somewhere — invisible to everyone in the store — a small slice of that sale flowed to an investor in New York who had nothing to do with making the drug, testing it, or selling it.
That investor is Royalty Pharma. You have probably never heard of it.
Most people hear "pharma" and picture white coats and laboratories. Royalty Pharma has none. No labs. No scientists. No sales force. No manufacturing plants. It is a company built on a single idea — buy the right to collect a percentage of a drug's sales, and let someone else do the hard part.
Legorreta left Lazard in 1996 and started Royalty Pharma in New York. He studied industrial engineering at Universidad Iberoamericana in Mexico City. He spent a decade doing mergers at Lazard in Paris and New York. Then he built something no one had tried before — a company that would buy royalty streams from universities, foundations, and small biotech firms. The scientists got cash today. Legorreta got a check every quarter, for years.
Here is where I start paying attention. In 2025, Royalty Pharma collected $3.25 billion in portfolio receipts — up 16% from the year before. It spent just 8.9% of that on operating costs. That left roughly $2.97 billion in Adjusted EBITDA from a team of about 100 people. One hundred. That is $32.5 million in receipts per employee. If you handed me a list of the most efficient businesses on the planet, this one belongs near the top. The company has deployed more than $25 billion since 1996, buying royalty interests on drugs that treat everything from cystic fibrosis to cancer to multiple sclerosis.
|
Take a look at this…
It's a radical "light-speed" device that's turning AI as we know it into "Accelerated AI", making it 100 times faster and 100 times more energy efficient.
In fact, Jensen Huang, Nvidia's founder and CEO, says this device is shattering the limitations of AI and without it, AI can't scale.
If you want to discover what this technology is, why Nvidia is betting billions on it…
And the one stock we believe could be the biggest winner when "Accelerated AI" goes mainstream…
Think about what 35-plus products means for you as an observer of this business. Even if one drug loses its patent or fades from the market, dozens more keep paying. In 2025, Royalty Pharma's top contributors included Vertex's cystic fibrosis franchise, GSK's respiratory drug Trelegy, and Johnson & Johnson's Tremfya. No single product dominates the portfolio enough to sink the ship.
Royalty Pharma doesn't set drug prices. It doesn't negotiate with insurance companies. It doesn't lobby Congress. The drug makers do all that. And when they raise prices — as pharmaceutical companies do, year after year — Royalty Pharma's slice of the revenue grows automatically. Vertex — whose revenue is driven by its cystic fibrosis drugs — reported $12 billion in total sales in 2025. Royalty Pharma collects a piece of that. The bigger the pie, the bigger the slice.
Here is the story that makes the whole model click. In 2014, the Cystic Fibrosis Foundation had a problem. It had invested $150 million to help Vertex Pharmaceuticals develop the drug Kalydeco and other treatments — a genuine breakthrough for children with cystic fibrosis. The drugs worked. But the foundation was a charity, not a hedge fund. It needed cash to keep funding research. So it sold its royalty rights to Royalty Pharma — for $3.3 billion. Read that again. A charity invested $150 million, earned back $3.3 billion, and poured the money into more research. Royalty Pharma, in turn, locked in a royalty stream on one of the most successful drug families in pharmaceutical history.
The flywheel works like this. Every year, Royalty Pharma takes the cash flowing in and deploys it into new royalty deals. In 2025 alone, the company announced $4.7 billion in new transactions — adding nine new therapies to its portfolio. Some are already approved and selling. Others are still in late-stage trials. When a development-stage drug gets approved, the royalty turns on — and the portfolio grows again. In the first quarter of 2026, portfolio receipts hit $925 million, up 10% from a year earlier. The company raised its full-year guidance. On the February 2026 earnings call, Legorreta called it plainly: "Royalty Pharma is a unique compounding machine. We grow consistently, year in and year out." I find it hard to disagree.
WHY THIS WORKS
No operating risk. Royalty Pharma doesn't run clinical trials, manage factories, or hire sales teams. It collects the right to a percentage, then waits.
Built-in diversification. Thirty-five-plus drugs across oncology, rare disease, respiratory, and neurology mean no single product can break the model.
Drug prices rise. Pharmaceutical companies raise list prices almost every year. Royalty Pharma's percentage stays the same, but the dollar amount grows.
New deals compound the base. Every dollar collected gets redeployed into new royalties — $25 billion deployed since 1996, with the pace accelerating.
Here is what most analysts miss: Royalty Pharma's portfolio includes royalties on 20 development-stage drug candidates that haven't been approved yet. If even a handful reach the market, those dormant royalties switch on — creating revenue streams the company has already paid for but that don't yet show up in any earnings report. The receipts you see today are only part of the story.
